JP2005529102A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529102A5
JP2005529102A5 JP2003583372A JP2003583372A JP2005529102A5 JP 2005529102 A5 JP2005529102 A5 JP 2005529102A5 JP 2003583372 A JP2003583372 A JP 2003583372A JP 2003583372 A JP2003583372 A JP 2003583372A JP 2005529102 A5 JP2005529102 A5 JP 2005529102A5
Authority
JP
Japan
Prior art keywords
aerosol
formulation
compound
formulation according
aerosol pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003583372A
Other languages
English (en)
Japanese (ja)
Other versions
JP5198716B2 (ja
JP2005529102A (ja
Filing date
Publication date
Priority claimed from GBGB0207899.6A external-priority patent/GB0207899D0/en
Application filed filed Critical
Publication of JP2005529102A publication Critical patent/JP2005529102A/ja
Publication of JP2005529102A5 publication Critical patent/JP2005529102A5/ja
Application granted granted Critical
Publication of JP5198716B2 publication Critical patent/JP5198716B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003583372A 2002-04-05 2003-04-01 フォルモテロールおよびシクレソニドのエアロゾル製剤 Expired - Fee Related JP5198716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0207899.6A GB0207899D0 (en) 2002-04-05 2002-04-05 Formoterol and cielesonide aerosol formulations
GB0207899.6 2002-04-05
PCT/US2003/010285 WO2003086349A1 (en) 2002-04-05 2003-04-01 Formoterol and ciclesonide aerosol formulations

Publications (3)

Publication Number Publication Date
JP2005529102A JP2005529102A (ja) 2005-09-29
JP2005529102A5 true JP2005529102A5 (enExample) 2006-06-01
JP5198716B2 JP5198716B2 (ja) 2013-05-15

Family

ID=9934322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003583372A Expired - Fee Related JP5198716B2 (ja) 2002-04-05 2003-04-01 フォルモテロールおよびシクレソニドのエアロゾル製剤

Country Status (9)

Country Link
US (1) US20050207984A1 (enExample)
EP (1) EP1492500B1 (enExample)
JP (1) JP5198716B2 (enExample)
AT (1) ATE401056T1 (enExample)
AU (1) AU2003262146A1 (enExample)
CA (1) CA2481187A1 (enExample)
DE (1) DE60322200D1 (enExample)
GB (1) GB0207899D0 (enExample)
WO (1) WO2003086349A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293833B2 (en) * 2002-12-12 2009-10-01 Covis Pharma B.V. Combination medicament
AU2004241746A1 (en) * 2003-05-22 2004-12-02 Nycomed Gmbh Salmeterol and ciclesonide combination
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (en) * 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
DE102006053374A1 (de) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US20120272951A1 (en) * 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2013167429A1 (de) * 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Zerstäuber
WO2016018892A1 (en) 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
WO2018059390A1 (zh) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 药物组合物
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12029562B2 (en) 2021-04-14 2024-07-09 Satio, Inc. Dermal patch system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE19541689A1 (de) * 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
AU710382B2 (en) * 1995-04-14 1999-09-16 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
DE19753301A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von Lactamen
US6264923B1 (en) * 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
KR100600423B1 (ko) * 1998-06-18 2006-07-13 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 2개 이상의 활성 물질을 포함하는 연무질 약제학적 제형
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CA2338680C (en) * 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
AU5858501A (en) * 2000-05-23 2001-12-03 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate

Similar Documents

Publication Publication Date Title
JP2005529102A5 (enExample)
US7273603B2 (en) HFC solution formulations containing an anticholinergic
US12090139B2 (en) Formulations comprising triptan compounds
ES2325316T3 (es) Composiciones farmaceuticas para el tratamiento del asma.
JP2001526685A (ja) 薬用エアゾール製品
JP2010505873A5 (ja) 化合物、会合複合体、及び会合複合体を形成する方法
JP2004521134A5 (enExample)
ATE401056T1 (de) Formoterol und ciclesonid aerosol-formulierungen
JP2005522421A5 (enExample)
WO2003066026A1 (en) Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier
IL104068A (en) Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
FR2798290A1 (fr) Formulation pharmaceutique de propionate de fluticasone
WO2016018892A1 (en) Method of preparing a pharmaceutical composition
JP2009541387A5 (enExample)
JP2002532428A (ja) フルオロアルカンおよびブデソニドを含有する医薬用エアゾール製剤
WO2008053250A3 (en) Formulations for delivery via pressurised metered dose inhalers comprising an essential oil as suspension stabiliser
HUP0302036A2 (hu) Glükokortikoidot tartalmazó készítmény bronchopulmonális betegségek kezelésére
JP2003530352A (ja) サルメテロール及びイプラトロピウムを含む医薬組成物
TW200913984A (en) Acetamide stereoisomer
JP2016517435A5 (ja) メロペネム誘導体及びその製造法
JP2013518061A5 (enExample)
JP2005501082A5 (enExample)
JP6815109B2 (ja) デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP2024546201A (ja) サルブタモールを含む医薬組成物
JP2002212063A5 (enExample)